DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> Asian Public Has ‘Hazy Perceptions’ About Air Pollution 28/03/2019 Divya Schlesinger Despite high public interest in severe air pollution episodes, the real long-term health impacts of air pollution are rarely discussed by news and social media in South and Southeast Asia, says a new study on public perceptions of the problem in one of the most dangerously polluted areas of the world. Image Credits: Vital Strategies. Continue reading -> UCLA Students Protest University Patent Claim On Prostate Cancer Treatment 13/03/2019 Divya Schlesinger Students at the University of California, Los Angeles (UCLA) renewed their protests today against a patent claim in an Indian High Court over a leading prostate cancer treatment, saying the claim, if successful, could make the drug unaffordable to millions of people in the developing world. Image Credits: Neda Ashtari. Continue reading -> How The Global Fund Plans To Raise US$ 14 Billion To Meet Its Goals 11/02/2019 Patralekha Chatterjee NEW DELHI, India -- Since its creation in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria has been an extraordinarily successful financing instrument in global health. It says it has saved 27 million lives as of the end of 2017 and reduced the number of deaths caused by AIDS, TB and malaria each year by one-third since 2002 in the countries where it invests. Now the Global Fund director has some ideas to increase funding to carry on the fight. Continue reading -> WHO Names Directors For Western Pacific, Southeast Asia 26/01/2019 William New The World Health Organization Executive Board today appointed the next directors for two of its its six regions. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> Asian Public Has ‘Hazy Perceptions’ About Air Pollution 28/03/2019 Divya Schlesinger Despite high public interest in severe air pollution episodes, the real long-term health impacts of air pollution are rarely discussed by news and social media in South and Southeast Asia, says a new study on public perceptions of the problem in one of the most dangerously polluted areas of the world. Image Credits: Vital Strategies. Continue reading -> UCLA Students Protest University Patent Claim On Prostate Cancer Treatment 13/03/2019 Divya Schlesinger Students at the University of California, Los Angeles (UCLA) renewed their protests today against a patent claim in an Indian High Court over a leading prostate cancer treatment, saying the claim, if successful, could make the drug unaffordable to millions of people in the developing world. Image Credits: Neda Ashtari. Continue reading -> How The Global Fund Plans To Raise US$ 14 Billion To Meet Its Goals 11/02/2019 Patralekha Chatterjee NEW DELHI, India -- Since its creation in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria has been an extraordinarily successful financing instrument in global health. It says it has saved 27 million lives as of the end of 2017 and reduced the number of deaths caused by AIDS, TB and malaria each year by one-third since 2002 in the countries where it invests. Now the Global Fund director has some ideas to increase funding to carry on the fight. Continue reading -> WHO Names Directors For Western Pacific, Southeast Asia 26/01/2019 William New The World Health Organization Executive Board today appointed the next directors for two of its its six regions. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Asian Public Has ‘Hazy Perceptions’ About Air Pollution 28/03/2019 Divya Schlesinger Despite high public interest in severe air pollution episodes, the real long-term health impacts of air pollution are rarely discussed by news and social media in South and Southeast Asia, says a new study on public perceptions of the problem in one of the most dangerously polluted areas of the world. Image Credits: Vital Strategies. Continue reading -> UCLA Students Protest University Patent Claim On Prostate Cancer Treatment 13/03/2019 Divya Schlesinger Students at the University of California, Los Angeles (UCLA) renewed their protests today against a patent claim in an Indian High Court over a leading prostate cancer treatment, saying the claim, if successful, could make the drug unaffordable to millions of people in the developing world. Image Credits: Neda Ashtari. Continue reading -> How The Global Fund Plans To Raise US$ 14 Billion To Meet Its Goals 11/02/2019 Patralekha Chatterjee NEW DELHI, India -- Since its creation in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria has been an extraordinarily successful financing instrument in global health. It says it has saved 27 million lives as of the end of 2017 and reduced the number of deaths caused by AIDS, TB and malaria each year by one-third since 2002 in the countries where it invests. Now the Global Fund director has some ideas to increase funding to carry on the fight. Continue reading -> WHO Names Directors For Western Pacific, Southeast Asia 26/01/2019 William New The World Health Organization Executive Board today appointed the next directors for two of its its six regions. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
UCLA Students Protest University Patent Claim On Prostate Cancer Treatment 13/03/2019 Divya Schlesinger Students at the University of California, Los Angeles (UCLA) renewed their protests today against a patent claim in an Indian High Court over a leading prostate cancer treatment, saying the claim, if successful, could make the drug unaffordable to millions of people in the developing world. Image Credits: Neda Ashtari. Continue reading -> How The Global Fund Plans To Raise US$ 14 Billion To Meet Its Goals 11/02/2019 Patralekha Chatterjee NEW DELHI, India -- Since its creation in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria has been an extraordinarily successful financing instrument in global health. It says it has saved 27 million lives as of the end of 2017 and reduced the number of deaths caused by AIDS, TB and malaria each year by one-third since 2002 in the countries where it invests. Now the Global Fund director has some ideas to increase funding to carry on the fight. Continue reading -> WHO Names Directors For Western Pacific, Southeast Asia 26/01/2019 William New The World Health Organization Executive Board today appointed the next directors for two of its its six regions. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
How The Global Fund Plans To Raise US$ 14 Billion To Meet Its Goals 11/02/2019 Patralekha Chatterjee NEW DELHI, India -- Since its creation in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria has been an extraordinarily successful financing instrument in global health. It says it has saved 27 million lives as of the end of 2017 and reduced the number of deaths caused by AIDS, TB and malaria each year by one-third since 2002 in the countries where it invests. Now the Global Fund director has some ideas to increase funding to carry on the fight. Continue reading -> WHO Names Directors For Western Pacific, Southeast Asia 26/01/2019 William New The World Health Organization Executive Board today appointed the next directors for two of its its six regions. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Names Directors For Western Pacific, Southeast Asia 26/01/2019 William New The World Health Organization Executive Board today appointed the next directors for two of its its six regions. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Antibiotic R&D Group To Screen Pharma Chemical Libraries For Antibacterial Compounds 14/12/2018 David Branigan The Global Antibiotic Research and Development Partnership (GARDP) and the pharmaceutical companies Eisai and Takeda signed an agreement this week for GARDP to access and screen the chemical libraries of Eisai and Takeda with the hope of finding chemical compounds with antibacterial properties. Continue reading -> Posts navigation Older postsNewer posts